This enabling patent provides processes to synthesize compounds that would otherwise be difficult and expensive to prepare with high purity and steroselectivity. These compounds are the lead drugs in the company’s antimetabolite development program focused on the treatment of cancers, especially brain tumors.
Donald Picker, COO of Edgeline Holdings, said: “This program is currently being developed to initiate human clinical trials and therefore having a cost effective synthesis to the compounds is an important advantage for the timely development of these drugs.”